Fate Therapeutics (FATE)
$0.75 +0.07 (10.72%)| Market Cap | 88.24M |
| Revenue (ttm) | 13.63M |
| Net Income (ttm) | -186.26M |
| EPS (ttm) | N/A |
| PE Ratio | 0.00 |
| Forward PE | N/A |
| Profit Margin | -1,366.54% |
| Debt to Equity Ratio | 0.00 |
| Volume | 3,608,200 |
| Avg Vol | 2,198,538 |
| Day's Range | N/A - N/A |
| Shares Out | 114.60M |
| Stochastic %K | 0% |
| Beta | 2.41 |
| Analysts | Sell |
| Price Target | $6.71 |
Latest News on FATE
Apr 2, 2025, 4:01 PM EDT - 3 days ago
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Mar 5, 2025, 4:01 PM EST - 4 weeks ago
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Mar 4, 2025, 4:01 PM EST - 4 weeks ago
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Feb 14, 2025, 4:01 PM EST - 7 weeks ago
Fate Therapeutics to Present at Upcoming Investor Conferences
Feb 4, 2025, 7:41 PM EST - 2 months ago
Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap
Dec 9, 2024, 4:01 PM EST - 4 months ago
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
Nov 26, 2024, 4:01 PM EST - 4 months ago
Fate Therapeutics to Present at Upcoming December Investor Conferences
Nov 20, 2024, 4:34 PM EST - 4 months ago
Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options
Nov 12, 2024, 4:01 PM EST - 5 months ago
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
Nov 8, 2024, 4:01 PM EST - 5 months ago
Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting
Sep 12, 2024, 4:01 PM EDT - 7 months ago
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
Aug 13, 2024, 4:05 PM EDT - 8 months ago
Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
May 29, 2024, 4:01 PM EDT - 11 months ago
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
May 11, 2024, 6:12 PM EDT - 11 months ago
Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript
May 9, 2024, 4:01 PM EDT - 11 months ago
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
May 9, 2024, 8:30 AM EDT - 11 months ago
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
May 3, 2024, 4:30 PM EDT - 1 year ago
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
Apr 29, 2024, 4:48 PM EDT - 1 year ago
Fate Therapeutics: As Its Rally Fizzles, We May Be Near The Bottom
Apr 29, 2024, 12:09 PM EDT - 1 year ago
Fate Therapeutics: Looking For A Potential Turnaround In 2024
Apr 22, 2024, 4:30 PM EDT - 1 year ago
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
Mar 19, 2024, 8:44 AM EDT - 1 year ago
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
Mar 1, 2024, 8:00 AM EST - 1 year ago
Fate Therapeutics to Present at Upcoming March Investor Conferences
Feb 26, 2024, 8:25 PM EST - 1 year ago
Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript
Feb 26, 2024, 4:01 PM EST - 1 year ago
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Feb 15, 2024, 8:00 AM EST - 1 year ago
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
Dec 13, 2023, 5:00 PM EST - 1 year ago
Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 8, 2023, 9:12 PM EST - 1 year ago
Fate Therapeutics, Inc. (FATE) Q3 2023 Earnings Call Transcript
Nov 8, 2023, 4:01 PM EST - 1 year ago
Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
Oct 25, 2023, 8:00 AM EDT - 1 year ago
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results
Aug 31, 2023, 8:00 AM EDT - 1 year ago
Fate Therapeutics to Present at Upcoming September Investor Conferences
Aug 8, 2023, 11:37 PM EDT - 1 year ago
Fate Therapeutics, Inc. (FATE) Q2 2023 Earnings Call Transcript
Aug 8, 2023, 4:01 PM EDT - 1 year ago
Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
Jul 28, 2023, 8:00 AM EDT - 1 year ago
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results
May 31, 2023, 8:00 AM EDT - 2 years ago
Fate Therapeutics to Present at Upcoming June Investor Conferences
May 3, 2023, 8:34 PM EDT - 2 years ago
Fate Therapeutics, Inc. (FATE) Q1 2023 Earnings Call Transcript
May 3, 2023, 4:01 PM EDT - 2 years ago
Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates
Apr 24, 2023, 8:00 AM EDT - 2 years ago
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results
Mar 21, 2023, 5:45 PM EDT - 2 years ago
FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
Feb 28, 2023, 10:57 PM EST - 2 years ago
Fate Therapeutics, Inc. (FATE) Q4 2022 Earnings Call Transcript
Feb 28, 2023, 4:01 PM EST - 2 years ago
Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
Feb 13, 2023, 8:00 AM EST - 2 years ago
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results